# Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

> **NCT06221462** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ningbo No.2 Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06221462
- **Lead sponsor:** Ningbo No.2 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2030-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221462, "Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06221462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*